Trials / Completed
CompletedNCT05351021
Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Mansoura University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
At present, there are no FDA-approved treatments for chemotherapy-induced neuropathy. Discrete neuro anti-inflammatory effects of metformin support its repurposing as a neuroprotective agent in patients with neurodegenerative diseases. Therefore, this study aims to evaluate the effect of metformin on the amelioration of paclitaxel induced neuropathy in cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | cidophage 850 gm twice daily |
| DRUG | Placebo | placebo twice daily for treatment period |
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2022-10-30
- Completion
- 2022-10-30
- First posted
- 2022-04-28
- Last updated
- 2023-03-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05351021. Inclusion in this directory is not an endorsement.